Holen Sie sich die Stockscreener-App
0.8546
1.48%
0.0125
Schlusskurs vom Vortag:
$0.8421
Offen:
$0.86
24-Stunden-Volumen:
26,446
Relative Volume:
0.18
Marktkapitalisierung:
$48.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.4801
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
+4.87%
1M Leistung:
-0.69%
6M Leistung:
-26.96%
1J Leistung:
-82.91%
1-Tages-Spanne:
$0.84
$0.8812
1-Wochen-Bereich:
$0.77
$0.8812
52-Wochen-Spanne:
$0.6101
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.8546 | 46.01M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Is Prelude Therapeutics Incorporated a good long term investmentGame-changing capital returns - jammulinksnews.com
What analysts say about Prelude Therapeutics Incorporated stockExponential wealth increase - jammulinksnews.com
Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
What drives Prelude Therapeutics Incorporated stock priceDynamic profit opportunities - jammulinksnews.com
what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser
Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser
What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Investment Community - Newser
Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPro Trader Stock Focus - Newser
How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser
Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks
Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks
Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus
Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World
20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World
Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan
Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo
Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus
Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance
Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India
Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com
AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE
Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug - Fierce Biotech
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MyChesCo
Mineralys Therapeutics to Present at Bank of America Health Care Conference - MyChesCo
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs - MyChesCo
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):